How Does Globus Medical Stock Compare With Peers?
With Globus Medical surging 36% in a Day, it makes sense to re-evaluate vs its peers. Consistently assessing alternatives is core to a sound investment approach. Here is how Globus Medical (GMED) stock stacks up against its peers in size, valuation, growth and margin.
- GMED’s operating margin of 15.7% is strong, lower than most peers – trailing SYK (19.6%).
- GMED’s revenue growth of 11.7% in the last 12 months is strong, outpacing SYK, MDT, ZBH, OFIX.
- GMED’s stock gained 2.3% over the past year and trades at a PE of 26.6, though peers like MDT delivered stronger returns.
As a quick background, Globus Medical provides healthcare solutions for musculoskeletal disorders and orthopedic trauma treatment, including fracture plates, compression screws, intramedullary nails, and external fixation systems worldwide.
A single stock can be risky, but there is a huge value to a broader, diversified approach. Should you buy one stock you like or build a portfolio designed to win across cycles? Our numbers show that the Trefis High Quality Portfolio has turned stock-picking uncertainty into market-beating consistency. This portfolio is incorporated in the asset allocation strategy of Empirical Asset Management — a Boston area wealth manager and Trefis partner — whose asset allocation framework yielded positive returns during the 2008-09 period when the S&P lost more than 40%.
| GMED | SYK | MDT | ZBH | OFIX | |
|---|---|---|---|---|---|
| Market Cap ($ Bil) | 11.3 | 136.1 | 118.2 | 17.5 | 0.6 |
| Revenue ($ Bil) | 2.8 | 24.4 | 34.2 | 8.0 | 0.8 |
| PE Ratio | 26.6 | 46.3 | 25.4 | 21.8 | -5.0 |
| LTM Revenue Growth | 11.7% | 11.0% | 5.0% | 5.5% | 4.3% |
| LTM Operating Margin | 15.7% | 19.6% | 19.4% | 18.7% | -11.6% |
| LTM FCF Margin | 20.6% | 16.7% | 15.5% | 17.6% | -0.4% |
| 12M Market Return | 2.3% | -2.9% | 8.1% | -17.8% | -17.9% |
Why does this matter? GMED just went up 40.7% in a month – peer comparison puts stock performance, valuation, and financials in context – highlighting whether it is truly outperforming, lagging behind, and above all – can this continue? Read Buy or Sell GMED Stock to see if Globus Medical holds up as a quality investment. Furthermore, there is always a risk of fall after a strong rally – see how the stock has dipped and recovered in the past through GMED Dip Buyer Analysis lens.
Revenue Growth Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| GMED | 11.7% | – | 60.6% | 53.3% | 6.8% |
| SYK | 11.0% | – | 10.2% | 11.1% | 7.8% |
| MDT | 5.0% | 3.6% | 3.6% | -1.4% | |
| ZBH | 5.5% | – | 3.8% | 6.5% | 1.6% |
| OFIX | 4.3% | – | 7.1% | 62.1% | -0.8% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| GMED | 15.7% | – | 8.7% | 12.9% | 23.1% |
| SYK | 19.6% | – | 20.7% | 19.1% | 16.9% |
| MDT | 19.4% | 19.5% | 17.1% | 18.7% | |
| ZBH | 18.7% | – | 19.9% | 19.6% | 17.2% |
| OFIX | -11.6% | – | -9.7% | -19.0% | -6.3% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| GMED | 26.6 | – | 109.0 | 49.0 | 39.2 |
| SYK | 46.3 | – | 45.8 | 35.9 | 39.2 |
| MDT | 25.4 | 22.0 | 29.8 | 27.5 | |
| ZBH | 21.8 | – | 23.7 | 24.8 | 115.5 |
| OFIX | -5.0 | – | -5.3 | -3.3 | -20.8 |
While peer comparison is critical, the Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.